Apyx Medical (NASDAQ:APYX) Releases Earnings Results, Beats Estimates By $0.05 EPS

Apyx Medical (NASDAQ:APYX) announced its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05, Zacks reports. The company had revenue of $12.88 million for the quarter, compared to the consensus estimate of $12.00 million. Apyx Medical had a negative return on equity of 158.22% and a negative net margin of 37.11%. Apyx Medical updated its FY 2025 guidance to EPS.

Apyx Medical Stock Up 15.5%

NASDAQ:APYX traded up $0.52 during mid-day trading on Friday, reaching $3.87. The company’s stock had a trading volume of 235,601 shares, compared to its average volume of 110,221. The company has a quick ratio of 3.95, a current ratio of 4.72 and a debt-to-equity ratio of 4.61. The firm has a market capitalization of $146.36 million, a PE ratio of -8.60 and a beta of 1.60. The stock has a fifty day moving average of $2.59 and a 200-day moving average of $2.09. Apyx Medical has a 1 year low of $0.76 and a 1 year high of $3.99.

Hedge Funds Weigh In On Apyx Medical

A number of large investors have recently bought and sold shares of APYX. Nantahala Capital Management LLC increased its holdings in shares of Apyx Medical by 2.5% in the 2nd quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock valued at $7,511,000 after acquiring an additional 80,000 shares during the period. Osaic Holdings Inc. bought a new position in shares of Apyx Medical during the 2nd quarter worth approximately $50,000. Finally, Vanguard Group Inc. boosted its stake in Apyx Medical by 3.6% in the third quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock valued at $3,272,000 after acquiring an additional 53,175 shares in the last quarter. Institutional investors own 55.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Apyx Medical in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.